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Aims: Endothelin (ET) receptor A antagonism decreases neuronal damage in experimental models of
stroke. Since large arteries like basilar artery contribute signiﬁcantly to total cerebrovascular resis-
tance and are major determinants of microvascular pressure, dysregulation of basilar artery function
may worsen stroke injury. ET-1 is involved in the regulation of basilar constriction. However, whether
stroke inﬂuences vasoreactivity of basilar artery and to what extent ET-1 contributes to basilar vascu-
lar dysfunction after stroke remained unknown. The goal of this study was to test the hypothesis that
ET-1 impairs basilar artery vasorelaxation after ischemia/reperfusion (I/R) injury via activation of ETA
receptor.
Main methods: MaleWistar rats were subjected to 3 hmiddle cerebral artery occlusion (MCAO) and 21 h reper-
fusion. One group received ETA receptor antagonist atrasentan (5 mg/kg, i.p.) at reperfusion. At 24 h, basilar ar-
teries were isolated from control non-stroked, stroked and stroked+atrasentan-treated animals for vascular
reactivity measurements using pressurized arteriograph.
Key ﬁndings: Acetylcholine (Ach)-induced maximum relaxation (Rmax) was decreased in stroked animals as
compared to non-stroked group and ETA antagonism partially restored it. There was also a trend for decreased
EC50 value for the antagonist treatment group indicating improved Ach sensitivity.
Signiﬁcance: These ﬁndings suggest that I/R not only affects vessels distal to the occlusion but also impairs relaxa-
tion of proximal large vessels. ET-1-mediated basilar artery dysfunction may contribute to neurovascular damage
after stroke and early restoration of vascular function by ET receptor antagonism after I/R injury may offer a thera-
peutic strategy.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Vascular endothelium plays an important role in regulating vas-
cular tone, coagulation and smooth muscle growth. Endothelin-1
(ET-1) generated by vascular endothelial cells and vascular smooth
cells is a potent vasoconstrictor with mitogenic and proﬁbrotic prop-
erties (Inoue et al., 1989). ET-1 can exert opposing vascular effects
via two G protein-coupled receptor subtypes, ETA and ETB. Activation
of ETA receptors on vascular smooth muscle cells lead to vasocon-
striction, while stimulation of ETB receptors on endothelial cells pro-
mote vasodilation via stimulation of nitric oxide production
(Edvinsson and Povlsen, 2011; Ergul, 2002; Haynes and Webb,
1998). Therefore, abnormal regulation of ET-1 system contributes
to the pathophysiology of various cardiovascular diseases including
ischemia/reperfusion (I/R) injury (Ergul, 2002). Many studies4, Department of Physiology,
, United States. Tel.: +1 706
.
-NC-ND license.showed increased ET levels after ischemic stroke both in patients
and experimental models (Barone et al., 1994; Thampatty et al.,
2011; Ziv et al., 1992) and that ETA receptor antagonists have neuro-
protective effects in both mechanical and embolic models of stroke
(Matsuo et al., 2001; Patel et al., 1996). Whether this effect is due
to direct neuronal protection and/or improvement of vascular func-
tion is not fully understood.
Cerebrovascular autoregulation is crucial for maintaining constant
blood ﬂow during changes of perfusion pressure (Owens, 2011). In
the brain, large extracranial and intracranial arteries (e.g., basilar arter-
ies) contribute signiﬁcantly to vascular resistance which attenuates
changes in downstream microvascular pressure during increases in
systemic arterial pressure (Cipolla, 2009). Therefore any alterations
in the reactivity of those vessels may lead to disturbance of this pro-
tective mechanism and could contribute to cerebrovascular disease.
Accordingly, the goals of the current study were to determine:
1) the impact of reperfusion injury on ET-1-mediated vasoconstric-
tion and endothelium-dependent relaxation of basilar arteries; and
2) the role of ETA receptors in this response in an experimental
model of stroke.
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Fig. 1. Effects of acute endothelin receptor antagonism on endothelin-1 mediated con-
tractility in stroked rats (S). A) Dose response curves to ET-1 demonstrated no change
in the contractility between control (C), stroked (S) and stroked rats treated with atra-
sentan (A). B) Sensitivity to ET-1 (EC50) did not differ among the groups.
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Animals and experimental groups
This study was conducted in accordance with National Institutes
of Health guidelines for the care and use of animals in research and
under protocols approved by the Division of Laboratory Animal Ser-
vices at the Georgia Health Sciences University. Male Wistar rats
(Harlan Laboratories, Indianapolis, IN) were housed four per cage
on a 12-h light/dark cycle.
Model of ischemia and drug treatment
Experimental groups included 1. Control (C, no stroke, n=8), 2.
Stroke (S, stroke+vehicle, n=10), and 3. Atrasentan (A, stroke+atra-
sentan, n=8). Transient middle cerebral artery occlusion (MCAO) was
induced as previously described (Ergul et al., 2007). The cerebral perfu-
sion was measured with a PIM3 laser Doppler scanning system (Peri-
med, Stockholm, Sweden) to evaluate basal perfusion as well as
perfusion changes following MCAO to conﬁrm successful occlusion. At
the end of ischemia (3 h MCAO), the animal was brieﬂy anesthetized,
atrasentan (5 mg/kg) was given by intraperitoneal injection, and reper-
fusion was initiated by ﬁlament withdrawal.
Pressurized arteriograph system and basilar artery preparation
At 24 h after ischemia, the animals were anesthetized and per-
fused with 100 ml of 0.01 M phosphate buffered saline (PBS). Basilar
arteries isolated from control, stroked or stroked-treated rats were
mounted on glass cannulas in an arteriograph chamber containing
5 ml HEPES buffer (NaCl, 130 mM; KCl 4 mM; MgSO4 1.2 mM;
NaHCO3 4 mM; HEPES 10 mM; KH2PO4 1.18 mM; Glucose 5.5 mM)
and the vessels were pressurized at 60 mmHg for 1 h. The Living Sys-
tems arteriograph chamber was connected to a temperature control-
ler that kept HEPES buffer at a constant temperature 37±0.5 °C
during the whole experiment. Lumen diameter was measured with
a video dimension analyzer both at the beginning and at the end of
the 1 h equilibration.
Vascular reactivity studies
Basilar lumen diameters of control, stroked and stroked rats treated
with atrasentan were measured after 2 min of exposure to increasing
concentrations of ET-1 (2×10-9, 10-8, 2×10-8, 10-7, 1.5×10-7 , 2×10-7
and 5×10-7 M) to determine the impact of ischemia and the treatment
on the contractility of the basilar artery. At the end of ET dose response,
the endothelium dependent relaxation was assessed by measuring the
lumen diameter in response to increasing concentrations of acetylcho-
line (Ach) (2×10-10 - 2×10-5 M). In preliminary experiments, when
higher doses of ET-1 were used to reach a plateau, vessels were either
unresponsive or did not relax in response to the following Ach treat-
ment. Therefore, dose–response curve to ET-1 was performed up to
5×10-7 M.Maximum response (Rmax) and EC50 values were calculated.
Infarct and edema analysis
At 24 h after ischemia, after the isolation of basilar arteries for vas-
cular function studies, brains were cut into 2-mm slices and stained
with 2% 2,3,5-triphenyltetrazolium chloride (TTC) for 5 min at 37 °C.
The image of the slices was scanned and the infarct volume was ana-
lyzed as previously described (Ergul et al., 2007). Total infarct volume
was calculated as percent volume of the total ischemic hemisphere.
Edema is reported as the percent increase in ischemic hemisphere
size to the contralateral hemisphere.Statistical analysis
A repeated-measures analysis of variances was used to determine
group differences (control versus stroked versus stroked-treated)
across ET-1 or Ach concentrations. Post-hoc group comparisons at
each concentration used a Tukey's adjustment for the multiple com-
parisons. Unpaired two-tailed t-test was used to compare infarct
size and edema between groups. Effects were considered statistically
signiﬁcant at pb0.05. Graphpad Prism 5 was used for all statistical
tests performed. Results are expressed as the means±SEM.
Results
Vascular reactivity
The sensitivity (EC50) and the contractile response to at 500 nm
ET-1 (maximum dose studied) were similar among the three groups
(Fig. 1A, B). Stroked rats exhibited impaired endothelium-
dependent relaxation following preconstriction with ET-1. Atrasentan
treatment caused a leftward shift and improved relaxation compared
to the stroked rats (Fig. 2A). Treatment with atrasentan did not only
improve endothelium-dependent relaxation but also increased the
maximum response (Fig. 2B). There was also a trend for decreased
EC50 value for the antagonist treatment group indicating improved
Ach sensitivity (Fig. 2C).
Infarct volume and edema
Treatment with atrasentan had no effect on infarct size or edema
as both parameters were similar in both groups (Fig. 3A, B). To ensure
that the drop in cerebral blood ﬂow (CBF) at MCAO is similar across
the study groups and also to determine whether there are differences
in CBF in the post-reperfusion period, the cerebral perfusion was
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Fig. 2. Effects of acute endothelin receptor antagonism on endothelium-dependent re-
laxation in stroked rats (S). in stroked rats. A) Dose response curves to Ach in ET-1-
preconstricted vessels demonstrated impaired relaxation in stroked rats (S) and ETA
antagonism with atrasentan (A) partially restored it. B) The magnitude of dilation
was less in stroked rats and atrasentan treatment improved relaxation. C) There was
a trend for improved sensitivity (EC50) to acetylcholine with ET receptor antagonism.
(*pb0.05 vs control, +pb0.05 and **pb0.01 vs stroked rats).
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Fig. 3. Effects of acute endothelin receptor antagonism on stroke outcomes. A) Infarct
size measured by TTC staining was similar in stroked and stroked rats treated with
atrasentan. B) There was no difference in edema between the two groups. C) Cerebral
blood ﬂow was signiﬁcantly decreased at ischemia and was partially restored at early
reperfusion in both groups.
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points (ischemia, right before reperfusion when antagonist was ad-
ministered and after reperfusion). Compared to baseline, there was
approximately a 50% decrease in cerebral perfusions in both vehicle
and atrasentan-treated rats and recovery after reperfusion was simi-
lar across the groups (Fig. 3C).Discussion
The present study demonstrates that while temporary focal brain
ischemia does not affect ET-1-mediated vasoconstriction of basilar ar-
teries, it impairs the ability of cerebral arteries to relax. Moreover,
acute treatment with atrasentan, an ETA receptor antagonist, given
right before reperfusion restored endothelium-dependent vasodila-
tion. The current study also provides evidence that acute short-term
use of atrasentan is not sufﬁcient to reduce infarct size or edema.
Taken together, these ﬁndings suggest that I/R injury causes cerebro-
vascular dysfunction of vessels upstream of occlusion in an ET-1-
dependent manner and that the role of ET-1 in the pathogenesis of ce-
rebral ischemic injury is complex.Regulation of cerebrovascular resistance and ultimately CBF is critical
for proper brain function (Faraci and Heistad, 1990). Temporary inter-
ruption of CBF as occurs in stroke has important implications. The cur-
rent treatment strategies focus on the reestablishment of CBF as soon
as possible to prevent infarct expansion but it is also known that reper-
fusion causes signiﬁcant tissue damage (Li et al., 2010; Takahashi et al.,
1997). Early hyperperfusion following ischemia contributes to blood
brain barrier disruption and edema (Sage et al., 1984). This period is usu-
ally followed by post-ischemic hypoperfusion andmultiple mechanisms
including increased vascular smoothmuscle tone of downstreammicro-
vessels (Cipolla and Bullinger, 2008; Cipolla et al., 2004; Takahashi et al.,
1997). In an early study, Takahashi et al. elegantly demonstrated that
vascular smooth muscle of the microvasculature in particular is highly
inﬂuenced by I/R injury (Takahashi et al., 1997). It is also known that
both microvasculature and macrovasculature are equally involved in
control of cerebrovascular resistance (Cipolla and Bullinger, 2008;
679M. Coucha et al. / Life Sciences 91 (2012) 676–680Faraci and Heistad, 1990). While signiﬁcant effort was directed towards
how ischemia induced by occlusion of a vessel modiﬁes structure and
function of the downstream microvasculature and ultimately cerebral
perfusion (Cipolla and Bullinger, 2008; Coulson et al., 2002), the impact
on upstream vessels is relatively understudied. Therefore, in the current
study we investigated the vascular reactivity of basilar arteries after I/R.
Given that ET-1 is one of the most potent vasoconstrictor identiﬁed to
date and that ET receptor antagonism decreases ischemic injury
(Gupta et al., 2005; Matsuo et al., 2001; Patel et al., 1996; Zhang et al.,
2008), we focused on ET-1-mediated vascular reactivity. While there
was no difference in ET-1-mediated vasoconstriction among control
(no stroke) and stroked (vehicle or atrasentan-treated) rats, the
endothelium-dependent vascular relaxation was signiﬁcantly impaired
by I/R and ETA receptor antagonism partially prevented this effect. We
studied vascular reactivity 21 h after the antagonist administration.
Thus, our data suggests that acute ET receptor antagonism has a long-
lasting effect on vascular function. It is highly possible that at early
time points after drug administration the restoration of vascular relaxa-
tion can be greater. Another possibility is the upregulation of ETB recep-
tors after ischemia. While we did not investigate the effect of ETB
receptor blockade on basilar artery reactivity, several studies demon-
strated that ischemia upregulates ETB receptors on vascular smooth
muscle cells (Henriksson et al., 2003; Stenman et al., 2002). Therefore,
it is highly possible that combined ETA and ETB receptor blockade may
fully restore large artery dysfunction following I/R injury and that
needs to be tested.
Several lines of evidence suggest that ET-1 contributes to ischemic
brain injury. First, direct administration of ET-1 into the brain causes
severe vasoconstriction and signiﬁcant reductions in CBF inducing
stroke (Macrae et al., 1993). Second, both experimental and clinical
studies reported increased plasma, cerebrospinal ﬂuid and tissue
ET-1 levels following I/R (Barone et al., 1994; Lampl et al., 1997; Loo
et al., 2002). Not only vasculature but also neuronal and glial ET-1
and ET receptors are altered following ischemia (Loo et al., 2002).
Third, gain and loss of function approaches indicated an important
role of ET-1 in ischemic brain injury. While endothelial over expres-
sion of ET-1 exacerbates infarct size and edema (Leung et al., 2009),
with the exception of one study (Chuquet et al., 2002), pharmacolog-
ical blockade of ET receptors in various experimental models of stroke
reduces neurovascular injury and improves outcomes. Chuquet and
colleagues demonstrated that selective ETB receptor blockade by di-
rect injection into the brain, reduces CBF and exacerbates neuronal
injury (Chuquet et al., 2002). Gupta et al., however, reported that
dual ETA and ETB antagonist TAK-044 pretreatment reduces ischemic
injury and this is associated with reduced oxidative markers and im-
proved functional outcomes (Gupta et al., 2005). Another study dem-
onstrated that selective ETA blockade given for 24 h starting 10 min, 1
or 3 h after middle cerebral artery occlusion decreases ischemic inju-
ry (Matsuo et al., 2001). A more recent study showed that when given
with the tissue plasminogen activator (tPA), the only FDA-approved
therapeutic for stroke treatment, ETA antagonism reduces the risk of
bleeding and provides neurovascular protection in an embolic
model of stroke (Zhang et al., 2008). In all these past studies, ET re-
ceptor blockade was administered either before stroke as a preven-
tive measure or continuously during the reperfusion period varying
from 22 to 72 h. The current study aimed to determine the acute
use of ET receptor blockade and ETA antagonist was given once right
before reperfusion with neurovascular injury being evaluated 21 h
later. We did not ﬁnd any differences in infarct size or edema be-
tween the groups. This may be due to the acute and the one-time ad-
ministration of the antagonist. Use of the receptor antagonist prior
to reperfusion may reduce neuronal injury. It is may also be due to
the greater magnitude of injury induced by 3 h MCAO used in the
current study. In a less severe model of ischemia, differences be-
tween vehicle and antagonist-treated groups may be easier to
detect.There are several limitations that need to be addressed. It has to be
recognized that the current study used healthy and young animals.
Even in this group, I/R injury inﬂuenced vascular function. We and
others have reported under disease states like diabetes, ET-1 causes
hyperactivity of basilar arteries and impairs endothelial function
(Harris et al., 2008; Matsumoto et al., 2004). Given that diabetes is a
risk factor for stroke, the impact of ischemic injury on cerebrovascular
function in diabetes needs to be further investigated. We also
reported that diabetes alters ET receptor expression (Kelly-Cobbs et
al., 2011). As such, role of both ETA and ETB receptors in the regulation
of vascular reactivity should be studied. The current study did not in-
clude functional outcome of stroke but based on the infarct sizes we
did not anticipate any differences in neurological function. We also
acknowledge that we did not study the effect of ET receptor blockade
on microvascular responses but rather focused on basilar arteries that
signiﬁcantly contribute to the regulation of cerebrovascular resistance.
Due to the shorter viability of basilar arteries after ischemic injury, we
were able to conduct only ET-1 and Ach dose response curves and
could not assess endothelium-independent vascular responsiveness
in the limited number of vascular segments we can isolate from one
animal. Nevertheless, this study provides important information for
the use of ET receptor antagonists in the setting of stroke. While the
acute use of ETA receptor blockade is able to restore vascular dysfunc-
tion, this does not translate into reduction of neuronal injury sug-
gesting that the role of ET-1 in ischemic injury is more complex.
Therefore, extended use of ETA receptor antagonist in the hours follow-
ing stroke is more desirable to reduce injury and improve outcomes.
Conclusion
The present study provides evidence that, in this model of I/R in-
jury, ET-1 plays an important role in the impairment of endothelium
dependent relaxation of cerebral vessels and that acute treatment
with ETA receptor antagonist could improve vascular function.
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